Thus, (i) the MHC-I expression, contrary to the downregulation observed in many cancer cells, is higher than in controls both in basal conditions and after DCA treatment; (ii) the HIF-1α levels are slightly reduced in basal conditions compared to control cells; and (iii) the migration capacity is diminished, as shown by a decrease in the average speed of mutant cells measured in vivo using microfluidic devices. This evidence concerns the gene HIF1A and cancer.